恒瑞医药(01276)：注射用瑞康曲妥珠单抗纳入突破性治疗品种名单

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received breakthrough therapy designation for its injectable SHR-A1811, marking the tenth indication for this drug [1] Group 1: Product Development - The injectable SHR-A1811 has been approved for domestic market launch in May 2025, targeting adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have previously received at least one systemic therapy [1] - The cumulative R&D investment for the injectable SHR-A1811 project has reached approximately 1.7725 billion yuan (unaudited) [1] Group 2: Market Potential - According to EvaluatePharma database, the global sales for similar products are projected to total approximately 6.557 billion USD by 2024 [1]